路云龙 (邮箱: yunlonglu12@njucm.edu.cn)，博士，副教授，硕士研究生导师。博士毕业于美国伊利诺伊大学芝加哥分校，现任教于医学院药理学系，中国化学会会员。

        主要研究领域包括：抗肿瘤靶向治疗药物研发与药理机制研究。主要针对乳腺癌，肝癌和肺癌等重大疾病，基于靶标进行合理药物设计与合成，对药理机制进行深入研究。目前以第一或通讯作者发表SCI论文18篇，收录于J Med Chem, Eur J Med Chem, Pharmacol Res, Chin Chem Lett, Chem Soc Rev等期刊，撰写ELSEVIER书籍章节，授权国家发明专利2项、国际专利2项。主持国家自然科学基金青年基金，江苏省教育厅，江苏省卫健委等基金项目，Eur J Med Chem和Biomed Pharmacother等期刊审稿人。

        近五年代表性科研论文

        1. Tianpeng Zheng, Shanglong Wang, Wukun Liu*, Yunlong Lu*. Targeting KAT6A/B as a new therapeutic strategy for cancer therapy. J. Med. Chem. 2025, 68, 2, 1002-1020.

        2.Yunlong Lu#, *, Zhihao Zhao#, Shanglong Wang, Tianpeng Zheng, Lijuan Liu, Yuqing Zhu, Wukun Liu*. Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant. Eur. J. Med. Chem. 2024, 279, 116897. 

        3.Yunlong Lu#, Zhenlin Liang#, Lijuan Liu#, Yanyu Zhou, Chao Liu, Zhihao Zhao, Tianpeng Zheng, Qianming Du*, Wukun Liu*. Discovery of novel quinoline scaffold selective estrogen receptor degraders (SERDs) for treatment of ER positive breast cancer with enhanced antiproliferative bioactivity through immunogenic cell death (ICD) effects. Eur. J. Med. Chem. 2024, 275, 116534. 

        4.Yunlong Lu#, Yuanhao Liu#, Zhenlin Liang, Xiaoyan Ma, Lijuan Liu, Zhenfan Wen, Iogann Tolbatov, Alessandro Marrone and Wukun Liu* NHC-gold(I)-alkyne complexes induced hepatocellular carcinoma cell death through bioorthogonal activation by palladium complex in living system. Chin. Chem. Lett. 2023, 34, 9, 108413. 

        5. Yunlong Lu, Xinyu Sheng, Chao Liu, Zhenlin Liang, Xin Wang, Lijuan Liu, Zhenfan Wen, Zhibin Yang, Qianming Du* and Wukun Liu* SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer. Pharmacol. Res. 2023, 190, 106731.